Second, in diseases with approved anti Her2/neu drug therapies (breast cancer, gastric cancer), ertumaxomab could expand the therapeutic spectrum, either in (anti Her2) resistant/refractory disease or additionally to established anti Her2 strategies, or even adjuvant concepts. The gene discussed is ERBB2; the disease is gastric cancer.